Merck & Co. Inc.
MRK | NYSE
$148.97
+$2.10 (+1.43%)
Sep 21, 2026, 11:06 AM ET · Market open
Company Profile
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Robert Davis | Chairman, President & Chief Executive Officer |
| Caroline Litchfield | Executive Vice President & Chief Financial Officer |
| Betty D. Larson | Executive Vice President & Chief Human Resources Officer |
| Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications |
| Dalton E. Smart | Senior Vice President of Finance, Principal Accounting Officer & Global Controller |
| David Michael Williams | Executive Vice President and Chief Information & Digital Officer |
| Dean Y. Li | Executive Vice President & President of Merck Research Laboratories |
| Jennifer L. Zachary | Executive Vice President & General Counsel |
| Johannes J. Oosthuizen | Executive VP and President of Oncology & MSD International |
| Peter Dannenbaum | Vice President of Investor Relations |
| Richard R. DeLuca Jr. | Executive Vice President & President of Merck Animal Health |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 3 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 12, 2026 | 4 | Filing |
| Aug 10, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 10-Q | Quarterly Report |
| Aug 07, 2026 | 13F-HR | Quarterly report filed by institutional managers, ... |
Merck & Co. Inc.
| Country | United States |
| IPO Date | Jan 12, 1978 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 74,000 |
| CEO | Robert Davis |
Contact Details
126 East Lincoln Avenue Rahway,
New Jersey 07065 United States
Stock Details
| Ticker Symbol | MRK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000310158 |
| CUSIP Number | 58933Y105 |
| ISIN Number | US58933Y1055 |
| SIC Code | 2834 |
Recent News
- 8 hours ago / businesswire.comMerck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
- 3 days ago / businesswire.comMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
- 3 days ago / zacks.comMerck (MRK) Outperforms Broader Market: What You Need to Know
- 6 days ago / marketbeat.comMerck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation
- 6 days ago / seekingalpha.comMerck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 7 days ago / globenewswire.comPerspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
- 10 days ago / zacks.comMRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
- 11 days ago / benzinga.comCongresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions
- 11 days ago / zacks.comMerck (MRK) Dips More Than Broader Market: What You Should Know
- 11 days ago / zacks.comMerck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Add to Watchlist
Select watchlists to add or remove MRK